Key players include ZipHealth (survey sponsor), pharmaceutical firms like Eli Lilly (offering employee access platforms), and survey bodies such as the International Foundation of Employee Benefit Plans (55% of employers cover GLP-1s for diabetes only in 2025) and KFF (nearly 20% of large employers cover for weight loss, rising to 43% for those with 5,000+ employees).[1][2][5][8] No specific legislation mandates coverage except North Dakota's 2025 ACA benchmark for small plans targeting diabetes prevention and obesity.[2]
GLP-1s, originally for diabetes, gained weight-loss traction post-2021 approvals; a November 2024 KFF poll showed 1 in 8 adults using them, with FDA approving Wegovy pills in December 2024 for accessibility.[headline] Demand surged (adult prescriptions from 0.9% in 2019 to 4% in 2024), driving employer restrictions like prior authorization amid cost spikes (66% of large employers report significant pharmacy spending impact).[2][6][8] Gen Z's prior skepticism (58% unlikely to use in 2024 Levity survey) shifted amid wellness trends and job market pressures.[headline]
Newsworthy now (April 2026 story) due to the fresh ZipHealth data highlighting Gen Z's job-switching prioritization of GLP-1s amid rising employer adoption (34% cover for weight loss vs. 26% prior year) and utilization (8.9% of claims), signaling a cultural shift where health benefits rival salary/PTO as talent attractors despite privacy taboos and costs.[1][3][5][9]